Oncology Today with Dr Neil Love: Key Presentations on Myeloproliferative Neoplasms from the 2022 ASH Annual Meeting

1

Introduction

00:00 • 3min

2

Optimizing the Care to Make People Live Longer

03:09 • 3min

3

The Rooks O'Lithin

06:08 • 4min

4

Anemia and Traumasotopenia - Is Pakritinib a Choice?

09:55 • 3min

5

Is Moma Litinib Good for Anemia?

12:26 • 3min

6

The Progression From Treatment With Ruxolitna

15:24 • 5min

7

IDH1N2 - Is JAC Inhibition Controlling Myal Aprylifaration?

19:55 • 2min

8

Caloritical Antibody

21:31 • 2min

9

Molecular Characterization of Response and Loss of Response

23:27 • 4min

10

Can Fedratinib Work in a Second Setting?

27:38 • 4min

11

Transplantation - When Is the Best Time?

31:58 • 2min

12

Inhibition of ACVR1 in Malle Fibrosis Transplant

33:55 • 3min

13

Phase 3 Random Study of Pakritinib

37:15 • 4min

14

Is Rucksolitinib a Marker of Longevity?

41:07 • 2min

15

Glucose Intolerance and Breast Cancer

43:29 • 2min

16

Navita Clocks and Bone Marrow Fibrosis

45:00 • 3min

17

Is Nevita Clax Working in Ml After Mylophybrasus

47:44 • 2min

18

Nevita Clax vs Ruxolietin

49:36 • 4min

19

Caloriticalin Mutation Positive Patients

53:13 • 3min

20

Are You a Candidate for This Antibody in Patients With Mallefibrosis?

55:53 • 2min

21

Polycytemia - Is There a Molecular Response to a Jack Inhibitor?

57:43 • 5min

22

Do You Have a Molecular Response in Pv?

01:02:16 • 2min

23

Ruxillatinum Is Not Approved for ET

01:04:30 • 5min

24

Beting Inhibitor for Malignant Cells

01:09:58 • 3min

25

Is There a Need to Eliminate Myeloma?

01:12:51 • 4min

26

Is There a Drug That Will Prevent Fibrosis Progression?

01:16:27 • 3min